Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections.

Masuo Y, Ohtaki T, Masuda Y, Tsuda M, Fujino M

Brain research1 Mar 1992Cited by 129 (Europe PMC)

PMID1324082DOI10.1016/0006-8993(92)90430-hPepBankPUB-01324082

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In rat dorsal hippocampal sections, [125I]VIP showed highly specific binding, but its specific binding was 10 times lower than that of [125I]PACAP.
In plain wordsIn rat brain tissue, VIP bound specifically to the hippocampus, but about 10 times less than PACAP did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableSpecific [125I]VIP binding in hippocampal sections compared with [125I]PACAP
Study
ratn: not reported in source
Rat brain sections (in vitro autoradiography)
Comparator
[125I]PACAP
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Radiolabeled PACAP and VIP showed highly specific binding to sections at the level of the dorsal hippocampus. The specific binding of [125I]PACAP was 10 times higher than that of [125I]VIP in hippocampal sections.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the characteristics and topographical distribution of [125I]PACAP binding sites compared with those of [125I]VIP binding sites in the rat brain.
Report a problemFND-0132408201
02LabEx vivo tissueActivity measurement
In rat brain sections, unlabeled PACAP effectively displaced [125I]VIP binding.
In plain wordsIn rat brain tissue, PACAP effectively pushed VIP off its binding sites.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseDisplacement of [125I]VIP binding by unlabeled PACAP
Study
ratn: not reported in source
Rat brain sections (in vitro autoradiography)
Comparator
[125I]VIP binding without unlabeled PACAP
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
while [125I]VIP binding was effectively displaced by unlabeled PACAP.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the characteristics and topographical distribution of [125I]PACAP binding sites compared with those of [125I]VIP binding sites in the rat brain.
Report a problemFND-0132408202
03LabEx vivo tissueActivity measurement
In rat brain sections, [125I]PACAP binding was scarcely displaced by unlabeled VIP.
In plain wordsIn rat brain tissue, VIP barely pushed PACAP off its binding sites.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeDisplacement of [125I]PACAP binding by unlabeled VIP
Study
ratn: not reported in source
Rat brain sections (in vitro autoradiography)
Comparator
[125I]PACAP binding without unlabeled VIP
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
[125I]PACAP binding was scarcely displaced by unlabeled VIP
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the characteristics and topographical distribution of [125I]PACAP binding sites compared with those of [125I]VIP binding sites in the rat brain.
Report a problemFND-0132408203
04LabEx vivo tissueActivity measurement
In rat brain sections, the amount of VIP/PACAP binding sites was negligibly low.
In plain wordsIn rat brain tissue, sites that bind both VIP and PACAP were very scarce.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableAmount of VIP/PACAP binding sites
Study
ratn: not reported in source
Rat brain sections (in vitro autoradiography)
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
However, the amount of VIP/PACAP binding sites was negligibly low.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the characteristics and topographical distribution of [125I]PACAP binding sites compared with those of [125I]VIP binding sites in the rat brain.
Report a problemFND-0132408204
05LabEx vivo tissueActivity measurement
In rat brain sections, the distribution of [125I]PACAP binding sites differed remarkably from that of [125I]VIP binding sites in the hippocampal formation, lateral hypothalamic area, substantia nigra pars compacta, pontine reticular nucleus and cerebellum.
In plain wordsIn rat brain tissue, VIP and PACAP binding sites were distributed differently in five brain regions, including the hippocampus and cerebellum.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableRegional distribution of [125I]VIP versus [125I]PACAP binding sites
Study
ratn: not reported in source
Rat brain sections (in vitro autoradiography)
Comparator
[125I]PACAP binding sites
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Distribution pattern was remarkably different from that of [125I]VIP binding sites in the hippocampal formation, lateral hypothalamic area, substantia nigra pars compacta, pontine reticular nucleus and cerebellum.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the characteristics and topographical distribution of [125I]PACAP binding sites compared with those of [125I]VIP binding sites in the rat brain.
Report a problemFND-0132408205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.